
Charlotte's Web Holdings, Inc.
96
Recent news coverage relevant to Charlotte's Web Holdings, Inc. is primarily industry-focused, including commodity price movements and earnings call transcripts of other companies. No direct recent operational or strategic updates specific to Charlotte's Web were identified.
- Soybeans posted gains following export announcements, reflecting broader agricultural commodity trends [N1].
- Hogs also posted gains across the board on Friday, indicating positive momentum in related agricultural markets [N2].
- Soybeans showed further price increases following export announcements, highlighting market volatility [N3].
- Earnings call transcripts for other companies such as Accelevation, Katapult, and OpenWorld were published, providing sector context but no direct updates on Charlotte's Web [N4][N5][N6].
- Stock indexes settled mostly lower with chipmakers sliding, reflecting broader market conditions [N7].
- Analysis of recent revenue trends for companies like AppLovin and CoreWeave was published, offering insight into tech sector dynamics [N8].
Charlotte's Web Holdings, Inc. operates as a market leader in the U.S. hemp-derived CBD wellness product sector. The company produces a variety of botanical-based products including full-spectrum CBD hemp extracts and functional mushroom gummies. It grows proprietary hemp through contract farming in multiple U.S. states and Canada (for Canadian market use only). The company manufactures products at its cGMP-compliant LOFT facility in Louisville, Colorado, which also houses its R&D division, CW Labs. Charlotte's Web is a public benefit company under British Columbia law, balancing shareholder value with social and environmental commitments. Strategic partnerships include a convertible debenture investment from a BAT subsidiary and a joint venture for botanical drug development. The company reported a net loss and maintains strong liquidity as of the latest quarter.
Charlotte's Web Holdings, Inc. is a benefit company focused on hemp-derived CBD and botanical wellness products, operating primarily in the U.S. market. The company manufactures and markets a range of products including hemp extracts and functional mushroom gummies from its cGMP-compliant facility in Louisville, Colorado. It maintains proprietary hemp farming contracts and invests in R&D through its CW Labs division. Financially, as of September 30, 2026, the company reported $11.36 million in cash, a strong liquidity position with a current ratio of 4.16, and a net loss of $3.46 million for the quarter. The company balances shareholder and public benefit interests as a legally designated benefit company. Recent news coverage is largely industry-focused with no direct operational updates. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Charlotte's Web benefits from its leadership in the U.S. hemp-derived CBD wellness market with a diversified product portfolio that includes innovative botanical products such as functional mushroom gummies. Its proprietary hemp genetics and vertically integrated supply chain support product quality and consistency. The company's investment in R&D and clinical trials through CW Labs may enhance product credibility and open new therapeutic opportunities. Strategic partnerships with British American Tobacco and joint ventures for botanical drug development provide access to capital and expertise. Strong liquidity ratios as of September 2026 support operational flexibility.
Charlotte's Web operates in a highly regulated and evolving industry with legal and regulatory uncertainties around hemp-derived CBD products. The company reported a net loss in the latest quarter, indicating ongoing profitability challenges. As a benefit company, balancing shareholder returns with public benefit objectives may create conflicts or limit financial optimization. Dependence on contract farming and third-party distributors could pose supply chain risks. The termination of the MLB promotional partnership may reduce brand exposure. Market competition and potential changes in consumer preferences present ongoing risks to growth and market share.
Charlotte's Web's moat is supported by its proprietary hemp genetics, vertically integrated supply chain including contract farming and in-house manufacturing, and established brand recognition in the U.S. CBD wellness market. Its status as a benefit company and commitment to scientific R&D through CW Labs contribute to differentiation. Strategic partnerships with major industry players like British American Tobacco and joint ventures for botanical drug development provide additional competitive advantages. The company's cGMP-compliant production facility and diversified product portfolio including functional mushroom gummies further strengthen its market position.
• Regulatory and Legal Risks: The hemp-derived CBD industry is subject to complex and evolving regulations that could impact product approvals, marketing, and sales. Changes in federal or state laws may affect the company's operations and product offerings.
• Profitability and Financial Risks: The company reported a net loss for the quarter ended September 30, 2026, indicating challenges in achieving sustained profitability. Continued losses could impact liquidity and operational capacity.
• Benefit Company Obligations: As a public benefit company, Charlotte's Web must balance shareholder interests with public benefit objectives, which may result in decisions that do not maximize shareholder value and could lead to legal challenges.
• Supply Chain and Production Risks: Reliance on contract farming and third-party distributors introduces risks related to supply consistency, quality control, and potential disruptions.
• Market Competition and Brand Exposure: The company faces competition in the CBD and botanical wellness markets. The termination of the MLB promotional rights agreement may reduce brand visibility and marketing reach.
Business trends: Expansion into botanical wellness products including functional mushrooms and ongoing R&D in hemp-derived compounds; strategic partnerships with BAT and joint ventures for botanical drug development.
Execution milestones: Maintaining cGMP-compliant production, advancing clinical trials via CW Labs, and managing liquidity with a current ratio above 4.0 as of Q3 2026.
Key risks: Regulatory uncertainties in hemp-derived CBD products, balancing benefit company obligations with shareholder value, profitability challenges, and supply chain dependencies.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Charlotte's Web Holdings, Inc. is a benefit company incorporated under British Columbia law and headquartered in Louisville, Colorado [S1].
- The company is a market leader in the U.S. for hemp extract and botanical-based wellness products, including brands such as Charlotte's Web™, CBD Medic™, and CBD Clinic™ [S1].
- Products include full-spectrum cannabidiol (CBD) hemp extracts, functional mushroom gummies, tinctures, gummies, capsules, topical creams, lotions, and pet products [S1].
- The company grows proprietary hemp domestically via contract farming in Arizona, Colorado, Kentucky, New Mexico, and Canada (Canadian hemp is used only for the Canadian market) [S1].
- Charlotte's Web operates a cGMP-compliant production facility called the LOFT in Louisville, Colorado, which handles production, quality control, distribution, and R&D [S1].
- The company has an internal R&D division called CW Labs focused on hemp-derived compounds and clinical trials [S1].
- Charlotte's Web does not produce or sell medicinal or recreational marijuana or high-THC cannabis products and has no near-term plans to do so [S1].
- The company is a single operating segment entity focused on hemp-derived CBD wellness products, which constitute the majority of its revenue [S1].
- Charlotte's Web has strategic partnerships including a convertible debenture investment from BT DE Investments, a subsidiary of British American Tobacco (BAT), and a joint venture entity DeFloria, Inc. with AJNA BioSciences and BAT for botanical drug development [S1].
- The company had an exclusive strategic partnership with Major League Baseball (MLB) which was terminated with waiver of remaining fees in 2025 [S1].
- Charlotte's Web launched a functional mushroom gummy product line in September 2024, expanding beyond hemp-based products [S1].
- The company is a public benefit company legally required to balance shareholder interests with public benefits, including sustainability and social contributions [S1].
- As of September 30, 2026, Charlotte's Web had cash and equivalents of $11.36 million, current assets of $31.38 million, current liabilities of $7.54 million, a current ratio of 4.16, and a cash ratio of 1.51 [S2].
- The company reported a net loss of $3.46 million and basic and diluted EPS of -$0.01 for the quarter ended September 30, 2026 [S2].
- There were no material changes to risk factors as disclosed in the 10-K for the year ended December 31, 2025 [S2].
- Recent news coverage includes industry-related commodity price movements and earnings call transcripts of other companies; no direct recent company-specific operational updates were found [N1][N2][N3][N4][N5][N6][N7][N8].
Generated 2026-11-15
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-15 | www.nasdaq.com | Soybeans Post Friday Gains Following Export Announcements | https://www.nasdaq.com/articles/soybeans-post-friday-gains-following-export-announcements
- N2 | 2026-11-15 | www.nasdaq.com | Hogs Post Gains Across the Board on Friday | https://www.nasdaq.com/articles/hogs-post-gains-across-board-friday
- N3 | 2026-11-15 | www.nasdaq.com | Soybeans Popping Higher on Friday Following Export Announcements | https://www.nasdaq.com/articles/soybeans-popping-higher-friday-following-export-announcements
- N4 | 2026-11-15 | www.nasdaq.com | Accelevation (ACCV) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/accelevation-accv-q3-2026-earnings-call-transcript
- N5 | 2026-11-15 | www.nasdaq.com | Katapult (KPLT) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/katapult-kplt-q3-2026-earnings-call-transcript
- N6 | 2026-11-15 | www.nasdaq.com | OpenWorld (OPNW) Q4 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/openworld-opnw-q4-2026-earnings-call-transcript
- N7 | 2026-11-15 | www.nasdaq.com | Stock Indexes Settle Mostly Lower as Chipmakers Slide | https://www.nasdaq.com/articles/stock-indexes-settle-mostly-lower-chipmakers-slide
- N8 | 2026-08-20 | www.nasdaq.com | AppLovin vs. CoreWeave: What Recent Revenue Trends Tell Investors | https://www.nasdaq.com/articles/applovin-vs-coreweave-what-recent-revenue-trends-tell-investors
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


